GLP-1 Drugs and Addiction: Why They May Help With Alcohol, Nicotine, and More

The Surprising Side Effect: Patients Stopped Wanting to Drink

When semaglutide patients started reporting they no longer wanted their evening glass of wine, their prescribing physicians initially dismissed it as incidental. But as the reports accumulated — and as more patients reported reduced interest in alcohol, nicotine, shopping, and gambling — the pattern became impossible to ignore.

GLP-1 receptor agonists may be the first pharmaceutical class with broad anti-addiction properties. The mechanism appears to be related to the same pathway that reduces food cravings — and it has profound implications for treating some of the most treatment-resistant conditions in medicine.

The Reward Pathway Connection

GLP-1 receptors are expressed throughout the body, including in the mesolimbic dopamine system — the brain's reward pathway. This circuit, centered on the nucleus accumbens and ventral tegmental area, mediates the experience of pleasure and motivation in response to rewards: food, drugs, sex, social interaction.

Addictive substances hijack this system, causing supraphysiologic dopamine release that creates craving, compulsive use, and difficulty stopping. Obesity and food addiction involve a similar dysfunction — hyperpalatable foods trigger dopamine responses that drive overeating beyond what hunger or nutrition require.

GLP-1 agonists appear to modulate this reward signaling. By acting on GLP-1 receptors in the nucleus accumbens and other reward-relevant structures, they dampen the dopaminergic response to rewarding stimuli — potentially including both food and drugs of abuse.

This is why patients describe the subjective experience as "the food noise turned off." The constant mental chatter about food, the preoccupation with eating, the pull toward hyperpalatable foods — it quiets. And apparently, so does the pull toward other rewarding substances.

Alcohol: The Best-Studied Non-Food Effect

Animal studies: Multiple preclinical studies show GLP-1 agonists reduce alcohol consumption in rodents, particularly in models of binge drinking and alcohol dependence. The effect is dose-dependent and specifically reversed by GLP-1 receptor antagonists — confirming the mechanism is GLP-1-mediated, not a general effect of the drugs.

Human observational data: In large healthcare database analyses, patients taking semaglutide or liraglutide for diabetes or obesity had significantly lower rates of alcohol use disorder diagnoses and alcohol-related hospitalizations compared to matched controls on other diabetes medications.

Randomized trials: Early results from the STAR study (semaglutide in alcohol use disorder) presented in 2024 showed semaglutide significantly reduced the number of heavy drinking days and total alcohol consumption compared to placebo in patients with alcohol use disorder. Effect sizes were meaningful — this wasn't a statistical artifact.

The likely mechanism: GLP-1 agonists reduce alcohol-induced dopamine release in the reward pathway, making alcohol less rewarding rather than just making it harder to drink. Patients don't feel like they're white-knuckling abstinence — they just lose the desire.

Nicotine and Smoking

Animal studies: GLP-1 agonists reduce nicotine self-administration in rodents and attenuate the rewarding effects of nicotine. The effect is seen in both naive animals and those with established nicotine dependence.

Human data: Multiple retrospective analyses show patients on GLP-1 therapy have higher smoking cessation rates and lower nicotine consumption. A large study published in eClinicalMedicine using UK Biobank data found semaglutide users had significantly lower rates of tobacco use disorder.

Mechanism: Same reward pathway modulation — nicotine-induced dopamine release appears dampened. Clinical trials specifically for smoking cessation are now underway.

Opioids and Other Substances

Data here is earlier but compelling. Animal studies consistently show GLP-1 agonists reduce opioid self-administration and attenuate opioid reward. Human observational data suggests lower rates of opioid use disorder and overdose in patients prescribed GLP-1 agonists.

For stimulants (cocaine, amphetamines), the picture is more complex, but animal data shows attenuation of cocaine-seeking behavior. Human trials are planned.

Gambling and other behavioral addictions are also being studied, with early data suggesting GLP-1 agonists may reduce compulsive gambling behavior via the same reward pathway mechanism.

Clinical Implications

If the emerging evidence holds up in rigorous trials:

Comorbidity treatment: Many people with substance use disorders also have obesity or type 2 diabetes — the target populations for GLP-1 drugs. A single medication could treat both conditions simultaneously.

Novel addiction treatment: Current pharmacological options for alcohol use disorder (naltrexone, acamprosate, disulfiram) have modest efficacy and low adoption. GLP-1 agonists could represent a paradigm shift — a well-tolerated drug with a novel mechanism.

Prevention: People with obesity are at elevated risk for substance use disorders. GLP-1 treatment for weight loss may simultaneously reduce addiction vulnerability.

What This Means for Patients

If you're on semaglutide or tirzepatide and notice reduced interest in alcohol, nicotine, or other addictive behaviors — this is expected and documented. It's not placebo, and it's not your imagination.

If you're considering GLP-1 therapy and have a history of substance use, this emerging mechanism is worth discussing with your physician. The data is not yet sufficient to prescribe GLP-1 drugs specifically for addiction treatment outside of clinical trials — but the trajectory of evidence is striking.

The idea that a weight loss drug might also treat addiction seemed implausible even five years ago. The reward pathway connection explains why the same drug that quiets the pull toward cake also quiets the pull toward the next drink. Food and drugs of abuse activate the same brain circuits. Modulating those circuits has broad effects that researchers are only beginning to characterize.

At Marrow, we note any history of substance use at intake, both for clinical safety reasons and because it may influence treatment expectations and outcomes. The full breadth of GLP-1 effects is still being mapped — and that map keeps expanding.